Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

BACKGROUND: Treatment options for metastatic renal cell carcinoma (RCC) are limited due to resistance to chemo- and radiotherapy. The development of small-molecule multikinase inhibitors has now opened novel treatment options. We evaluated the influence of the receptor tyrosine kinase inhibitor AEE7...

Descripción completa

Detalles Bibliográficos
Autores principales: Juengel, Eva, Engler, Johanna, Natsheh, Iyad, Jones, Jon, Mickuckyte, Ausra, Hudak, Lukasz, Jonas, Dietger, Blaheta, Roman A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693528/
https://www.ncbi.nlm.nih.gov/pubmed/19473483
http://dx.doi.org/10.1186/1471-2407-9-161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693528/
https://www.ncbi.nlm.nih.gov/pubmed/19473483
http://dx.doi.org/10.1186/1471-2407-9-161

Ejemplares similares